^
Association details:
Biomarker:TSC2 overexpression
Cancer:Hepatocellular Cancer
Drug:everolimus (mTOR inhibitor)
Direction:Resistant
Evidence:
Evidence Level:
Resistant: C3 – Early Trials
New
Title:

Loss of Tuberous Sclerosis Complex 2 (TSC2) as a Predictive Biomarker of Response to mTOR Inhibitor Treatment in Patients with Hepatocellular Carcinoma

Excerpt:
We retrospectively assessed 36 patients with advanced HCC who had received sorafenib...Two (5.6%) patients received everolimus after sorafenib failure. The TSC2-high patient (TSC2 H-score = 230) experienced a shorter PFS of 2.1 months compared with the TSC2-moderate patient (TSC2 H-score = 150), whose PFS was 5.8 months...The TSC2-moderate HCC patient with lung and brain metastasis experience stable disease after two cycles of everolimus treatment, whereas the TSC2-high HCC patient with lung metastasis experienced rapid progression of the lung metastasis.
DOI:
10.1016/j.tranon.2016.08.009